Clinical Trials Finder
Independent ClinicalTrials.gov directory
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

ClinicalTrials.gov ID: NCT06921785

Public ClinicalTrials.gov record NCT06921785. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced May 6, 2026, 8:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Study identification

NCT ID
NCT06921785
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
1,220 participants

Conditions and interventions

Interventions

  • Atezolizumab Drug
  • Bevacizumab Drug
  • Rilvegostomig Drug
  • Tremelimumab Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 5, 2025
Primary completion
Mar 15, 2029
Completion
Mar 13, 2030
Last update posted
Jan 8, 2026

2025 – 2030

United States locations

U.S. sites
32
U.S. states
19
U.S. cities
30
Facility City State ZIP Site status
Research Site Phoenix Arizona 85054 Not yet recruiting
Research Site Tucson Arizona 85724 Not yet recruiting
Research Site Palo Alto California 94304 Recruiting
Research Site Santa Monica California 90404 Not yet recruiting
Research Site New Haven Connecticut 06511 Not yet recruiting
Research Site Newark Delaware 19713 Not yet recruiting
Research Site Jacksonville Florida 32224 Not yet recruiting
Research Site Atlanta Georgia 30322 Withdrawn
Research Site Fayetteville Georgia 30214 Not yet recruiting
Research Site Chicago Illinois 60637 Not yet recruiting
Research Site Shreveport Louisiana 71103 Not yet recruiting
Research Site Detroit Michigan 48202 Not yet recruiting
Research Site Grand Rapids Michigan 49503 Recruiting
Research Site Rochester Minnesota 55905 Not yet recruiting
Research Site New Brunswick New Jersey 08901 Recruiting
Research Site New York New York 10029 Not yet recruiting
Research Site New York New York 10032 Not yet recruiting
Research Site New York New York 10065 Not yet recruiting
Research Site Cleveland Ohio 44195 Withdrawn
Research Site Oklahoma City Oklahoma 73104 Withdrawn
Research Site Philadelphia Pennsylvania 19107 Not yet recruiting
Research Site Pittsburgh Pennsylvania 15237 Not yet recruiting
Research Site Austin Texas 78705 Not yet recruiting
Research Site Dallas Texas 75390 Withdrawn
Research Site El Paso Texas 79902 Not yet recruiting
Research Site Houston Texas 77058 Not yet recruiting
Research Site San Antonio Texas 78240 Not yet recruiting
Research Site Tyler Texas 75702 Not yet recruiting
Research Site Blacksburg Virginia 24060 Not yet recruiting
Research Site Fairfax Virginia 22031 Not yet recruiting
Research Site Seattle Washington 98109 Not yet recruiting
Research Site Milwaukee Wisconsin 53226 Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 172 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06921785, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 8, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06921785 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →